Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.

ABSTRACT: Exposure to dengue virus (DENV) is thought to elicit lifelong immunity, mediated by DENV-neutralizing antibodies (nAbs). However, Abs generated by primary infections confer serotype-specific protection, and immunity against other serotypes develops only after subsequent infections. Accordingly, the induction of these nAb responses acquired after serial DENV infections has been a long-sought-after goal for vaccination. Nonetheless, it is still unclear if tetravalent vaccines can elicit or recall nAbs. In this study, we have characterized the responses from a volunteer who had been previously exposed to DENV and was immunized with the live attenuated tetravalent vaccine Butantan-DV, developed by the NIH and Butantan Institute. Eleven days after vaccination, we observed an ∼70-fold expansion

SUBMITTER: Magnani DM 

PROVIDER: S-EPMC5660501 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature